This Barclays research summary provides updates on Americas small-cap stocks including Cushman & Wakefield, Arvinas, Braze, and Tenable Holdings, following recent investor events and trial results.
Key Takeaways
- 1.Tenable Holdings expects to reach the 'Rule of Forty' financial performance metric by the end of FY29.
- 2.The failure of the LUMA trial (BIIB122) for Parkinson's disease is considered to have a limited impact on the core investment thesis for Arvinas (ARVN).
- 3.Braze Inc. is positioned for a favorable 1Q27 setup driven by strong enterprise bookings momentum and an easier year-over-year comparison.
Table of Contents
- Summary of Changes
- Publications Summary
- Financial Services
- Healthcare
- Technology
- Analyst(s) Certification(s)
- Important Disclosures
- Availability of Disclosures
- Risk Disclosure(s)
- Guide to the Barclays Fundamental Equity Research Rating System
- Stock Rating
- Industry View
- Distribution of Ratings
- Guide to the Barclays Research Price Target
- Types of investment recommendations produced by Barclays Equity Research
- Disclosure of other investment recommendations produced by Barclays Equity Research
- Legal entities involved in producing Barclays Research
- Disclaimer
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Brendan LynchEtzer DaroutRaimo LenschowSaket Kalia
Securities
TENBARVNBRZECWKBIIB
Themes
Rule of FortyClinical Trial Read-throughsEnterprise Software Bookings Momentum
Regions
North AmericaUnited StatesCanada
